Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Johnsson, E.
572  Ergebnisse:
Personensuche X
?
1

A RAC-GEF network critical for early intestinal tumourigene..:

Pickering, K. A. ; Gilroy, K. ; Cassidy, J. W....
Nature Communications.  12 (2021)  1 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
2

O148 SHORT-TERM RESULTS OF A RANDOMIZED CONTROLLED TRIAL OF..:

Nilsson, K ; Klevebro, F ; Szabo, E...
Diseases of the Esophagus.  32 (2019)  Supplement_2 - p. , 2019
Link: https://doi.org/10.1093/..
 
?
3

Validation of instruments for the assessment of dysphagia d..:

Persson, J ; Engström, C ; Bergquist, H..
Diseases of the Esophagus.  32 (2018)  9 - p. , 2018
Link: https://doi.org/10.1093/..
 
?
4

Dapagliflozin reduces albuminuria in patients with diabetes..:

Heerspink, H. J. L. ; Johnsson, E. ; Gause‐Nilsson, I...
Diabetes, Obesity and Metabolism.  18 (2016)  6 - p. 590-597 , 2016
Link: https://doi.org/10.1111/..
 
?
5

CA-039: Pas de majoration du risque d'événements cardiovasc..:

Ricci, L. ; Gause-Nilsson, I. ; Sonesson, C...
Diabetes & Metabolism.  42 (2016)  - p. A45 , 2016
Link: https://doi.org/10.1016/..
 
?
6

One-year efficacy and safety of saxagliptin add-on in patie..:

Matthaei, S. ; Aggarwal, N. ; Garcia-Hernandez, P....
Diabetes, Obesity and Metabolism.  18 (2016)  11 - p. 1128-1133 , 2016
Link: https://doi.org/10.1111/..
 
?
7

Long-term maintenance of efficacy of dapagliflozin in patie..:

Leiter, L. A. ; Cefalu, W. T. ; de Bruin, T. W. A....
Diabetes, Obesity and Metabolism.  18 (2016)  8 - p. 766-774 , 2016
Link: https://doi.org/10.1111/..
 
?
8

Comparison of the pharmacokinetics and pharmacodynamics of ..:

Tang, W. ; Leil, T. A. ; Johnsson, E...
Diabetes, Obesity and Metabolism.  18 (2016)  3 - p. 236-240 , 2016
Link: https://doi.org/10.1111/..
 
?
9

Efficacy and safety of triple therapy with dapagliflozin ad..:

Mathieu, C. ; Herrera Marmolejo, M. ; González González, J. G....
Diabetes, Obesity and Metabolism.  18 (2016)  11 - p. 1134-1137 , 2016
Link: https://doi.org/10.1111/..
 
?
10

CA-047: Efficacité et sécurité de la dapagliflozine chez le..:

Ricci, L. ; Kosiborod, M. ; Gause-Nilsson, I...
Diabetes & Metabolism.  42 (2016)  - p. A48 , 2016
Link: https://doi.org/10.1016/..
 
?
11

CA-048: La dapagliflozine réduit l'albuminurie en plus d'in..:

Ricci, L. ; Lambers Heerspink, H. ; Johnsson, E...
Diabetes & Metabolism.  42 (2016)  - p. A48 , 2016
Link: https://doi.org/10.1016/..
 
?
12

Erratum to: Abstracts of the 51st Annual Meeting of the EAS..:

Lambers Heerspink, H. J. ; Johnsson, E. ; Gause-Nilsson, I..
Diabetologia.  58 (2015)  12 - p. 2901-2901 , 2015
Link: https://doi.org/10.1007/..
 
?
13

Dapagliflozin‐induced weight loss affects 24‐week glycated ..:

Sjöström, C. D. ; Hashemi, M. ; Sugg, J...
Diabetes, Obesity and Metabolism.  17 (2015)  8 - p. 809-812 , 2015
Link: https://doi.org/10.1111/..
 
?
14

Durability and tolerability of dapagliflozin over 52 weeks ..:

Matthaei, S. ; Bowering, K. ; Rohwedder, K....
Diabetes, Obesity and Metabolism.  17 (2015)  11 - p. 1075-1084 , 2015
Link: https://doi.org/10.1111/..
 
?
15

Dose‐ranging study with the glucokinase activator AZD1656 a..:

Kiyosue, A. ; Hayashi, N. ; Komori, H...
Diabetes, Obesity and Metabolism.  15 (2013)  10 - p. 923-930 , 2013
Link: https://doi.org/10.1111/..
 
1-15